CL2022000656A1 - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
CL2022000656A1
CL2022000656A1 CL2022000656A CL2022000656A CL2022000656A1 CL 2022000656 A1 CL2022000656 A1 CL 2022000656A1 CL 2022000656 A CL2022000656 A CL 2022000656A CL 2022000656 A CL2022000656 A CL 2022000656A CL 2022000656 A1 CL2022000656 A1 CL 2022000656A1
Authority
CL
Chile
Prior art keywords
new compounds
present description
compounds
diseases
fibrotic
Prior art date
Application number
CL2022000656A
Other languages
English (en)
Inventor
Tomas Fex
Bengt Ohlsson
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of CL2022000656A1 publication Critical patent/CL2022000656A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente descripción se proporciona un compuesto de fórmula I, en donde R1, R2, R3 Y1, Y2, Y3, Y4, R4, R5 y R6 son como se definen en la presente descripción, dichos compuestos son útiles en el tratamiento de enfermedades autoinmunitarias y/o fibróticas, que incluyen enfermedades pulmonares intersticiales, tales como fibrosis pulmonar idiopática y sarcoidosis.
CL2022000656A 2019-09-20 2022-03-17 Nuevos compuestos CL2022000656A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201913603A GB201913603D0 (en) 2019-09-20 2019-09-20 New compounds

Publications (1)

Publication Number Publication Date
CL2022000656A1 true CL2022000656A1 (es) 2022-11-04

Family

ID=68425648

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000656A CL2022000656A1 (es) 2019-09-20 2022-03-17 Nuevos compuestos

Country Status (14)

Country Link
US (1) US20220388994A1 (es)
EP (1) EP4031240A1 (es)
JP (1) JP2022549086A (es)
KR (1) KR20220101071A (es)
CN (1) CN114786774A (es)
AU (1) AU2020351301A1 (es)
BR (1) BR112022003130A2 (es)
CA (1) CA3152218A1 (es)
CL (1) CL2022000656A1 (es)
CO (1) CO2022003091A2 (es)
GB (1) GB201913603D0 (es)
IL (1) IL291172A (es)
MX (1) MX2022003286A (es)
WO (1) WO2021053344A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202013721D0 (en) * 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
EP4313953A1 (en) * 2021-03-23 2024-02-07 Vicore Pharma AB Selective angiotensin ii receptor ligands
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds
WO2023281271A1 (en) * 2021-07-09 2023-01-12 Vicore Pharma Ab New selective angiotensin ii compounds
WO2023193733A1 (zh) * 2022-04-06 2023-10-12 武汉人福创新药物研发中心有限公司 一种at2r激动剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
ES2295339T3 (es) 2001-05-31 2008-04-16 Vicore Pharma Ab Compuestos tricilicos utiles como agonistas de la angiotensina ii.
AU2003302106A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
EP3229839A1 (en) 2014-12-12 2017-10-18 Vicore Pharma AB New methods and uses
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
KR20170122754A (ko) 2015-03-02 2017-11-06 바이코어 파마 아베 폐섬유증을 치료하기 위한 안지오텐신 ii 수용체 작용제
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy

Also Published As

Publication number Publication date
KR20220101071A (ko) 2022-07-19
BR112022003130A2 (pt) 2022-05-17
IL291172A (en) 2022-05-01
JP2022549086A (ja) 2022-11-24
AU2020351301A1 (en) 2022-03-17
MX2022003286A (es) 2022-04-12
CN114786774A (zh) 2022-07-22
GB201913603D0 (en) 2019-11-06
CO2022003091A2 (es) 2022-04-19
US20220388994A1 (en) 2022-12-08
WO2021053344A1 (en) 2021-03-25
EP4031240A1 (en) 2022-07-27
CA3152218A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
CL2022000656A1 (es) Nuevos compuestos
CL2023000580A1 (es) Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii
PH12021551167A1 (en) New heterocyclic compounds
MY196327A (en) New Anthelmintic Quinoline-3-Carboxamide Derivative
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
PH12020500257A1 (en) Quinoline derivatives for treating infections with helminths
PE20211698A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
PE20151162A1 (es) Compuestos heterociclicos inhibidores del colesterol 24-hidroxilasa (ch24h)
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20142376A1 (es) Fluormetil-5,6-dihidro-4h-[1,3]oxazinas
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
MX358149B (es) Derivado de pirazoloquinolina.
PE20140105A1 (es) Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos
UY36702A (es) Piridinas sustituidas y métodos de uso
MX2017009540A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd).
TW201713650A (en) NADPH oxidase 4 inhibitors
EA202190654A1 (ru) Гетероциклическое соединение
PH12017500095A1 (en) Imidazopyridazine compounds
MX2018010852A (es) Metodos para tratar la depresion con antagonistas del receptor de orexina-2.
PH12018501849A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
MX2018007852A (es) Compuestos de indolinona y su uso en el tratamiento de enfermedades fibróticas.
PE20150021A1 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
MX2016015090A (es) Compuestos antihelminticos.